Table 1.
Candidate subtypes were determined depending on the tumour marker elevation status and lymphovascular invasion status.
| Subtypes | Tumour marker elevation | Lymphovascular invasion | |||
|---|---|---|---|---|---|
| None | Slight | Mild | Severe | ||
| ABC1 | Both CEA and CA19-9 | B | C | C | C |
| Either CEA or CA19-9 | A | B | C | C | |
| None | A | A | B | C | |
| ABC2 | Both CEA and CA19-9 | B | B | C | C |
| Either CEA or CA19-9 | A | B | C | C | |
| None | A | A | B | C | |
| ABC3 | Both CEA and CA19-9 | A | B | C | C |
| Either CEA or CA19-9 | A | B | C | C | |
| None | A | B | B | C | |
| ABC4 | Both CEA and CA19-9 | A | B | C | C |
| Either CEA or CA19-9 | A | B | C | C | |
| None | A | A | B | C | |
| ABC5 | Both CEA and CA19-9 | B | B | C | C |
| Either CEA or CA19-9 | B | B | C | C | |
| None | A | B | B | C | |
| AB | Both CEA and CA19-9 | A | A | B | B |
| Either CEA or CA19-9 | A | A | B | B | |
| None | A | A | A | B | |
CA19-9, Cancer antigen 19-9; CEA, Carcinoembryonic antigen.